Retour

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly

- 22 Janvier 2025 - 1  mn de lecture

The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.

En rapport Clinical Trials

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis – Study 1
22 Janvier 2025 1  mn de lecture

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis – Study 1
Effects of triptorelin when given every 6-months under the skin to adult males with cancer in the prostate
22 Janvier 2025 1  mn de lecture

Effects of triptorelin when given every 6-months under the skin to adult males with cancer in the prostate
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
22 Janvier 2025 1  mn de lecture

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
A Study to Assess the Safety and Efficacy of IPN10200 of in Adult Participants With Upper Limb Spasticity.
22 Janvier 2025 1  mn de lecture

A Study to Assess the Safety and Efficacy of IPN10200 of in Adult Participants With Upper Limb Spasticity.
Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.
22 Janvier 2025 1  mn de lecture

Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
22 Janvier 2025 1  mn de lecture

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
22 Janvier 2025 1  mn de lecture

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic...
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
22 Janvier 2025 1  mn de lecture

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
22 Janvier 2025 1  mn de lecture

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
22 Janvier 2025 1  mn de lecture

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)